Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS

被引：1

作者：

Saad, F. ^{[1
]}

Hussain, M. ^{[2
]}

Tombal, B. ^{[3
]}

Fizazi, K. ^{[4
]}

Sternberg, C. N. ^{[5
]}

Crawford, E. D. ^{[6
]}

Boegemann, M. ^{[7
]}

Tutrone, R. ^{[8
]}

Littleton, N. ^{[9
]}

Srinivasan, S. ^{[10
]}

Verholen, F. ^{[11
]}

Kuss, I. ^{[12
]}

Smith, M. R. ^{[13
,14
]}

机构：

[1] CHUM, Hosp St Luc, Urol Dept, Montreal, PQ, Canada

[2] Northwestern Univ Feinberg Sch Med, Feinberg Sch Med, Chicago, IL USA

[3] Clin Univ St Luc, IREC, Div Urol, Brussels, Belgium

[4] Univ Paris Saclay, Gustave Roussy, Dept Canc Med, Villejuif, France

[5] Weill Cornell Med, Div Hematol & Oncol, Belfer Res Bldg, New York, NY USA

[6] UC San Diego Sch Med, Dept Urol, La Jolla, CA USA

[7] Munster Univ Med Ctr, Urol, Munster, Germany

[8] Chesapeake Urol, Urol, Towson, MD USA

[9] Bayer Ltd, Med Oncol, Dublin, Ireland

[10] Bayer Healthcare Pharmaceut Inc, Stat, Whippany, NJ USA

[11] Bayer Consumer Care AG, GU Franchise, Med Affairs, Basel, Switzerland

[12] Bayer AG, Clin Dev, SBU Oncol, Berlin, Germany

[13] Massachusetts Gen Hosp Canc Ctr, Genitourinary Oncol Program, Boston, MA USA

[14] Harvard Med Sch, Boston, MA USA

来源：

关键词：

D O I：

10.1016/j.annonc.2023.09.2734

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1784P

引用

页码：S964 / S964

页数：1